Tocilizumab in GCA - three year data from GiACTA on steroid exposure and time to flare: - steroid-sparing benefit persists in both new-onset and relapsing disease - in avoiding flares, benefit for weekly dosing in both new-onset and relapsing disease OP0027 #EULAR2020 @RheumNow https://t.co/tGU6ayglHW